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Abstract
Breast cancer was traditionally perceived as a single disease; however, recent advances in gene expression and gen-
omic profiling have revealed that breast cancer is in fact a collection of diseases exhibiting distinct anatomical fea-
tures, responses to treatment and survival outcomes. Consequently, a number of schemes have been proposed for
subtyping of breast cancer to bring out the biological and clinically relevant characteristics of the subtypes.
Although some of these schemes capture underlying molecular differences, others predict variations in response
to treatment and survival patterns. However, despite this diversity in the approaches, it is clear that molecular
mechanisms drive clinical outcomes, and therefore an effective scheme should integrate molecular as well as clinical
parameters to enable deeper understanding of cancer mechanisms and allow better decision making in the clinic.
Here, using a large cohort of 550 breast tumours fromThe Cancer Genome Atlas, we systematically evaluate a
number of expression-based schemes including at least eight molecular pathways implicated in breast cancer and
three prognostic signatures, across a variety of classification scenarios covering molecular characteristics, biomarker
status, tumour stages and survival patterns.We observe that a careful combination of these schemes yields better
classification results compared with using them individually, thus confirming that molecular mechanisms and clinical
outcomes are related and that an effective scheme should therefore integrate both these parameters to enable a
deeper understanding of the cancer.
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INTRODUCTION
With an estimated 1.38 million new cases and
458 000 deaths worldwide every year, breast cancer
is the most common malignancy among women in
both the developed and developing world [1, 2].
Historically, breast cancer was perceived as a single
disease with varying histopathological features and
responses to systemic treatment [3]. However, the
advent of high-throughput platforms for gene ex-
pression profiling [4, 5] and whole-genome and
whole-exome sequencing [6–9] have enabled studies
that have challenged this view and brought to the
fore the concept that breast cancer consists of a col-
lection of different diseases that affect the same organ
site but have different risk factors, clinical presenta-
tion, histopathological features, survival outcomes
and responses to systemic therapies [3, 10, 11]. This
heterogeneity poses a severe challenge for accurate
diagnosis of patients for optimal dosage and extent of
treatment and to estimate risk factors associated with
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their disease. For example, a study analysing breast
cancer cases in the United States reported between
1976 and 2008 estimated that 1.3 million women
were over-diagnosed and over-treated as a result of
regular mammogram screening during this 30-year
period [12]; the long-term side effects of the treat-
ments among survivors may be significant [2]. Such
heterogeneity also complicates understanding of the
underlying tumour biology—e.g. the genetic, epi-
genetic and host factors underpinning aberrant
signalling pathways—for development of new thera-
peutic strategies. Consequently, a number of classifi-
cation schemes have been devised to stratify breast
tumours, attempting to comprehend the intricate
biological mechanisms driving these tumours and
to allow more effective decision making in clinical
trials and treatments.
Although breast cancer has provided an excellent
test bed for development and testing of classification
schemes, their sheer number and lack of concord-
ance have made it difficult to judge their applicabil-
ity, and therefore standardize them. For example,
while some schemes quantify molecular differences
between tumours (molecular subtyping), others pre-
dict survival outcomes (prognosis) and therapeutic
responses (prediction); it is not clear to what extent
these molecular differences are related to clinical out-
comes, or whether this relationship influences thera-
peutic strategies and clinical decisions.
Here, we review the different schemes developed
for breast cancer classification including anatomical
systems, gene expression and genomic signatures and
multi-omic integrative models. Using gene expres-
sion profiles of 550 patients from The Cancer
Genome Atlas (TCGA) [6], we evaluate 10 expres-
sion-based signatures for molecular subtyping and
prognostic ability. We note that molecular charac-
teristics strongly determine clinical outcomes, and
therefore an effective predictive model should inte-
grate both these parameters to enable deeper under-
standing of cancer mechanisms and development of
better treatment strategies.
BREASTCANCERCLASSIFICATION
SCHEMES
Based on the purpose and the type of information
(dataset) used, breast cancer classification schemes can
be roughly distributed into five classes, though these
classes can be overlapping (Figure 1). Histological
grading and TNM staging (tumour size, lymph
node and metastatic spread based) are based on the
physical or anatomical properties of the cancer and
quantify its aggressiveness. The expression-based
schemes predominantly use microarray or qRT-
PCR expression profiles and can be divided into
molecular subtyping, and prognostic and predictive
gene signatures. The genomic profile-based schemes
use mutational profiles of tumour genomes, and with
the recent advent in high-throughput sequencing
technologies have gained much interest. Network-
based methods integrate molecular interactions with
expression and mutational profiles (multi-omics in-
tegration) to capture network-aggregated properties
of breast cancer.
Histological grading
Very simply, histological grade is the description of
the tumour based on the abnormality of tumour cells
relative to normal cells when observed under a
microscope. Typically, a numerical grade (1, 2, 3
or 4) is assigned to the tumour depending on the
extent of this abnormality. Grade-1 tumour cells
appear highly similar to normal cells, and these tu-
mours tend to spread slowly. In contrast, cells of
Grade 3 and 4 tumours appear highly dissimilar
from normal cells, and these tumours grow rapidly
and spread faster than lower-grade tumours.
The histological grading system most widely
adopted in breast cancer is the Nottingham system
[13, 14], and is included as part of prognostic indices
such as the Nottingham Prognostic Index. This
index combines tumour grade and lymph node
stage of the TNM system (discussed next) for deter-
mining the treatment for breast cancer patients in the
UK [15, 16].
Tumour size, lymph node invasion and
metastatic spread
In the TNM system, T appended with a number
(0–4) is used to describe the size and location of
the tumour: T0—no evidence of tumour; T1—the
invasive part of the tumour has size 20mm and is
carcinoma in situ, confined within the ducts or lob-
ules of breast tissue; T2—the invasive part of
the tumour is 20–50mm; T3—the invasive part
>50mm; and T4—the tumour has grown into the
chest wall and skin with signs of inflammation. Four
stages are likewise recognized for lymph node inva-
sion: N0—no cancer cells are found in the lymph
nodes; N1—the cancer has spread to three nodes;
N2—the cancer has spread to four to nine nodes;
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and N3—the cancer has spread to 10 nodes. The
spread is measured as distant metastasis with the fol-
lowing stages: M0—the cancer has not metastasized;
and M1—there is evidence of metastasis to another
body part. The cancer is staged by combining these
T, N and M classifications. In breast cancer, there are
five stages 0–4, of which stage 0 corresponds to non-
invasive ductal carcinoma in situ and stages 1 through
4 are used for invasive breast cancer.
Gene expression-based classification
Molecular biology studies such as gene expression
profiling have shown that response to treatment,
and therefore clinical decision making, is not deter-
mined by anatomical factors (such as tumour size or
lymph node status) per se, but rather by intrinsic mo-
lecular characteristics of the tumours [3, 10, 11, 17].
Consequently, a number of landmark studies [4, 5,
18–23] uncovered multi-gene expression markers
that are independent of classical anatomical markers,
from the compendia of genome-wide mRNA pro-
files of patients. These clinically motivated markers,
also called gene signatures, correlate with the molecular
characteristics of tumours (molecular subtypes) [4, 5],
aggressiveness markers such as proliferation or grade
[11, 22], survival outcomes (prognosis) [19–21] and
response to therapy [17, 24, 25].
Molecular or ‘intrinsic’subtyping
One of the first applications of microarray-based
gene-expression analysis to the study of breast
cancer was in the assessment of diversity at a molecu-
lar level. Starting with an initial set of 8102 genes
from 65 tumour expression samples, 456 ‘intrinsic’
genes (those that varied more in expression between
tumours than between repeated samples of the same
tumour) were identified that hierarchically clustered
the samples based on molecular characteristics [4].
Subsequent validation on an independent dataset of
78 breast cancers confirmed the robustness of this
classification [5]. These seminal studies revealed
that ER-positive and ER-negative tumours (ER:
estrogen receptor) are molecularly different, and
the intrinsic genes identified at least four distinct sub-
types (luminal, HER2-enriched, basal-like and
normal-like). Luminal tumours are mostly ER-posi-
tive, and are further classified into luminal-A, which
are histologically low-grade, and luminal-B, which
express lower levels of hormone receptors and are
mostly high-grade. HER2-positive tumours show
amplification and over-expression of the ERBB2
gene, and are mostly high grade. On the other
hand, basal-like tumours are ER-negative, PR-
negative (PR: progesterone receptor) and HER2-
negative (hence ‘triple-negative’). These subgroups
correspond reasonably well to clinical characteriza-
tion on the basis of ER and HER2 status, as well as
proliferation markers or histological grade [4, 5].
Although these intrinsic subtypes have been
adopted to build breast cancer prognostic and thera-
peutic-response prediction models such as the
PAM50 signature [18], the classification is limited
by its close correspondence to ER, PR and HER2
status, and analyses have suggested that these do not
have sufficient prognostic or predictive value [10].
First-generation prognostic signatures
Over the past decade several groups have pursued the
development of multi-gene prognostic signatures
that classify patients with good prognosis, who
hence can forgo chemotherapy, and those with
Figure 1: Histopathological, anatomical, expression and genomic schemes for classification of breast cancers.
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poor prognosis and metastasis risk. Here, we
highlight three widely adopted signatures—
MammaPrint, Wang-76 and OncotypeDX; for a
comprehensive review readers are referred to [3, 11].
70-gene signature. MammaPrint (Agendia,
Amsterdam, Netherlands) was the first successful
prognostic gene signature, and is a microarray
test approved by the US Food and Drug
Administration for prognosis of patients with TNM
stage 1 or 2, node-negative, invasive breast cancer of
tumour size 50mm. This signature was constructed
from an empirical microarray analysis of 78 breast
cancers from patients <55 years with node-negative
tumours 50mm [19]. A supervised analysis of
25 000 genes from the expression profiles of these
patients identified a set of 70 genes that accurately
predicted poor prognosis disease (development of
distant metastasis within 5 years) on an independent
cohort of 295 invasive breast cancers [26].
Subsequent studies confirmed the test’s prognostic
potential in node-positive [27] and HER2-positive
[28] tumours, and its correlation with chemotherapy
sensitivity [29]. However, the discriminatory power
of the signature for ER-negative cancers was noted
to be very low [30].
76-gene signature. This signature was developed on
the basis of supervised analysis of 115 breast cancers,
of which 80 were ER-positive, but unlike in
MammaPrint, ER-positive and ER-negative cancers
were analysed separately [20]. This identified two
separate sets of genes to predict poor prognosis, 60
genes for patients with ER-positive disease and 16
genes for ER-negative disease, which were then vali-
dated on an independent set of 171 patients.
However, subsequent studies showed that this signa-
ture had the same limitations as MammaPrint, and
the 16-gene signature did not have sufficient power
to predict outcome for patients with ER-negative
and HER2-postive cancers [31, 32].
OncotypeDX. In parallel with microarray-based sig-
natures, OncotypeDX (Genomic Health, USA) was
developed using qRT-PCR-based expression pro-
files [21], and is widely adopted for clinical practice
in the United States. A mathematical function [re-
currence score (RS)] in OncotypeDX uses a 21-gene
expression profile to predict the risk of distant relapse
at 10 years for patients with ER-positive, lymph
node-negative cancers. The association between
RS and distant relapse was examined retrospectively
in 668 patients treated with tamoxifen, and RS pre-
dicted 10-year distant recurrence rates as 7, 14 and
30% for the low-risk, intermediate-risk and high-risk
categories of patients, respectively [33]. In addition,
the association of RS with benefit from adjuvant
chemotherapy in ER-positive, node-negative, tam-
oxifen-treated patients was examined in 651 patients.
Higher scores were associated with greater benefit
from adjuvant chemotherapy, and more critically,
lower scores were associated with a lack of even
marginal benefit from chemotherapy [34].
Second-generation prognostic signatures
Analysis of breast tumours from large cohorts has
revealed that although many genes, most of which
are related to cell cycle and proliferation, predict the
outcome of ER-positive cancers, fewer genes predict
the outcome of ER-negative cancers, with the
number strongly dependent on the dataset analysed
[10, 35]. Genes involved in the immune response
provide additional prognostic information for ER-
negative and highly proliferative ER-positive cancers
[22], and this has led to the development of immune
response-based signatures [36]. Further, the analysis
of genes expressed in the stromal compartment of
breast cancers has led to the development of
stroma-related prognostic signatures [22, 37].
Predictive signatures
Beyond prognostic classifiers, the challenge is to pro-
vide physicians with biomarkers that can predict
response (or lack of response) to treatment [38].
OncotypeDX has been shown to be associated
with benefit from adjuvant chemotherapy [10, 11,
17]. Many groups have focused on neoadjuvant ther-
apy to estimate chemotherapy sensitivity. For ex-
ample, a 30-gene signature developed in 82 breast
cancer patients receiving neoadjuvant chemotherapy
estimated the response of 51 independent patients
with higher predictive value than clinical variables
such as age, grade and ER status [24, 25]. Another
approach to develop multi-gene classifiers of chemo-
sensitivity is based on ‘metagenes’, that is, groups of
co-expressed genes associated with a small number of
biological processes. A retrospective microarray ana-
lysis of ER-negative breast cancers demonstrated that
increased stromal metagene expression predicted re-
sistance to chemotherapy [37].
Despite these promising initial results, signatures of
chemotherapy sensitivity have so far seen limited use
in clinical practice; only ER and HER2 are currently
used as predictive markers (for selecting patients
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likely to respond to endocrine therapy and trastuzu-
mab, respectively).
Pathway-based signatures
The ability to capture breast cancer heterogeneity
based on the activity of oncogenic pathways [39]
has been demonstrated for molecular subtyping of
breast cancer [40, 41]. The rationale behind these
methods is that different oncogenic pathways are
dysregulated in cancer subtypes that are fundamen-
tally different in their molecular mechanisms, so by
tracking the activities of these pathways it is possible
to stratify tumours and predict clinical outcomes
[42]. A cohort of 1143 tumours was classified into
17 subgroups using the expression profiles of genes in
ER/PR, MYC, RAS, AKT, EGFR/TGFb,
STAT3/TNFa, P53-apoptosis and PI3K pathways,
corresponding to the intrinsic subtypes including
basal-like (subgroups 2, 5 and 8), luminal-A (sub-
groups 11 and 17), luminal-B (subgroups 3, 4, 6, 9
and 16) and HER2-enriched (subgroups 7 and 10)
subtypes [40]. Different subgroups exhibited distinct
patterns of pathway activity. For example, the basal
subgroups exhibited low ER/PR and high Myc and
Ras activity, whereas the luminal subgroups gener-
ally exhibited the reverse pattern. Further, pathway
activity identified finer subtypes within the intrinsic
subtypes. For example, among the basal subgroups,
subtypes 2 and 5 exhibited low EGFR activity,
whereas subtype 8 showed high EGFR expression.
Validation on an independent dataset of 547 tumours
indicated that the predicted subgroups corresponded
well to the clinical properties of these tumours.
Issues with gene expression-based signatures
A comprehensive study comparing 47 published
gene signatures with 1000 randomly generated
gene sets strikingly found that most signatures were
not more strongly associated with breast cancer out-
come than were the random gene sets [23]. In fact,
repeated trials showed that 11 (23%) of these signa-
tures exhibited a weaker association than the random
median, and only 18 (40%) met the biological and
statistical relevancy criteria of showing better associ-
ation than the top 5% of random sets. Similar results
have been reported in other studies [43]. This high
chance for discordance among the signatures has
been attributed to the fact that expression data con-
tain large numbers of highly correlated variables, and
therefore different combinations of these variables
can be selected to build similarly accurate prediction
methods [11, 43]. A consequential limitation is that
many of the signatures include genes which have no
relevance to tumour biology, and thus seldom yield
interesting insights into the mechanism of disease
progression.
A meta-analysis [44] of 3000 tumours for recur-
rence found that most signatures separated the
low-proliferative luminal-A tumours at low risk of
recurrence, but these signatures were less informative
for the ER-negative basal-like and HER2þ tu-
mours; in fact, most signatures assigned a high risk
of recurrence to almost all ER-negative tumours.
This was because most of the signatures include a
substantial proportion of cell-cycle progression
genes. Although these genes are unquestionably im-
portant, including independent prognostic informa-
tion (e.g. immune-related genes [44]) is important in
the case of ER-negative tumours.
Classification based on genomic
profiling
Advances in high-throughput whole-genome and -
exome sequencing have revealed complex landscapes
of cancer genomes, allowing comprehensive investi-
gation into the molecular basis of cancers [6–9, 45,
46]. These studies have revealed a fundamental
observation: there is considerable heterogeneity
among the tumours of different patients, which
could potentially have significant implications on
how patients are stratified for clinical trials and treat-
ments. However, much of this inter-patient genomic
heterogeneity is because of the background muta-
tions (‘passengers’), while only a limited number of
genes (‘drivers’) are responsible for the molecular and
clinical differences [45, 47]. By mapping these
driver-event frequencies onto the molecular sub-
types, we see that luminal-A tumours harbour a
high frequency of PI3KCA mutations (45% cases),
while luminal-B in TP53 and PI3KCA (29% each).
On the other hand, TP53 mutations occur in a ma-
jority of basal-like tumours (80%), but are nearly
absent in luminal tumours. HER2-enriched tumours
show frequent copy-number amplification of HER2
(80%), and mutations in TP53 (72%) and PI3KCA
(39%) [6].
Similarly, a study analysing 2000 breast tumours
[7] found that copy-number drivers such as MYC,
CCND1 and PPP2R2A/B account for significant dif-
ferences between tumours, and identified up to 10
‘integrative’ clusters that finely divide the intrinsic
subtypes; each of these clusters correlates with dis-
tinct clinical outcomes. For example, an ER-positive
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cluster corresponding to luminal tumours exhibited
poor prognosis, representing a high-risk subgroup
within luminal tumours, and this cluster showed
amplification in CCND1.
At the time of writing, the COSMIC list (http://
cancer.sanger.ac.uk/cancergenome/projects/census/)
contains 19 genes implicated in breast cancer, and this
list is likely to expand to 35–40 genes as the genes
from the above sequencing studies are validated.
However, in an analysis of 100 breast cancer genomes
[48], tumours initiated from mutations in <10 genes
(the minimum being 6) were observed, indicating that
different combinations of these 19 driver genes could
initiate tumours, and possibly different kinds of tu-
mours, thus explaining in part the genetic basis for
heterogeneity of breast cancer.
The question that arises as to which of these com-
binations give rise to tumours with distinct under-
lying disease mechanisms and prognosis. A key
observation is that all of the driver genes can be clas-
sified into a limited number of known signalling
pathways, and deregulation of different genes
within the same pathway or sub-pathway leads to
similar outcomes. This suggests that tumours could
be stratified based on these pathways or networks of
pathways [7, 45, 49, 50].
Network-based classification
Based on the observation that important aspects of
inter-patient or inter-tumour heterogeneity can be
summarized into common pathways, we can use
molecular networks of protein–protein, functional
and pathway interactions to integrate data from
large-scale expression and mutation profiling studies
[49, 50]. In a recent study [49], mutations were inte-
grated through molecular networks using a ‘net-
work-smoothing’ approach to identify distinct
network modules associated with tumour subtypes
and thereby stratify patients. Application of this net-
work-based stratification method to ovarian cancer
samples identified up to four subtypes that discrimi-
nated survival outcomes of patients better than earlier
subtypes, based solely on expression data. In [50], a
probabilistic approach was used to combine PPI net-
works, expression and mutation datasets, to track
network modules that showed differential behaviour
between tumour subtypes, and were related to dis-
ease prognosis. These network modules could asso-
ciate tumour subtypes to disease mechanisms such as
functional deficit in DNA damage through muta-
tions in genes such as ATM, BRCA1 and BRCA2,
or to those responsible for drug resistance such as
fibroblast signalling genes [51]. It will be valuable
to see what subtypes in breast cancer this method
can identify.
EVALUATIONOF
EXPRESSION-BASED SIGNATURES
Because disease mechanism can be associated with
clinical outcomes including survival times and re-
sponse to therapy (above), an important goal of
cancer classification should be to examine whether
prognostic signatures are related to disease mechan-
ism; that is, whether specific molecular markers play
a functional role in the pathogenesis of cancer. For
gene expression signatures the results have been
modest, which is hardly surprising because different
subsets of genes are highly correlated with each other
and can equally discriminate samples for prognosis.
Therefore, much of the functional interpretation of
prognostic signatures should be treated with caution.
On the other hand, deregulation in different onco-
genic pathways has been shown to be responsible for
the intrinsic differences between tumours. It remains
to be determined if these differences amount to dif-
ferences in clinical outcomes.
Here, we analyse this relationship between mo-
lecular mechanisms and clinical outcomes. We com-
pile a list of oncogenic pathways implicated in breast
cancer and widely used prognostic signatures, and
evaluate them for their ability to classify breast tu-
mours based on (i) molecular properties and (ii) sur-
vival outcomes. These experiments are by no means
exhaustive, but reveal valuable insights into the link
between molecular and clinical characteristics via
these signatures and pathways.
Materials and methods
Our experiments were conducted in two parts, to
evaluate these signatures (from now on we refer to
all prognostic signatures and biological pathways as
just signatures, unless specifically distinguished) for
their ability to:
(i) classify breast tumours into known molecular or
intrinsic subtypes (basal-like, HER2-enriched,
luminal-A and luminal-B), ER-status (ERþ
and ER) and tumour stages (early and
advanced); and
(ii) differentiate good and bad disease prognosis in
patients.
466 Taherian-Fard et al.
Downloaded from https://academic.oup.com/bib/article-abstract/16/3/461/244930/Breast-cancer-classification-linking-molecular
by Queensland University of Technology user
on 26 September 2017
We downloaded gene expression datasets of 547
breast cancer patients (as of April 2013) from TCGA
(http://cancergenome.nih.gov/) [6]. Next, we com-
piled eight biological pathways implicated in breast
cancer, four prognostic signatures and one blood-
protein biomarker set (Table 1 and Supplementary
Figure S7) from the literature [18–20, 52, 53],
MSigDB (http://www.broadinstitute.org/gsea/
msigdb/index.jsp) and KEGG databases [54]. For
(i), we trained a support vector machine-classifier
on each of these signatures and evaluated their clas-
sification performance using 10-fold cross-validation,
benchmarked against the PAM50 signature used to
assign the original labels in TCGA. A signature con-
taining genes with high variability in expression
across two or more subtypes is more likely to differ-
entiate between the subtypes, and this in turn trans-
lates to higher classification accuracy. For (ii), we
evaluated the prognostic ability of these signatures
using Kaplan–Meier survival curves plotted using
KM-Plotter (www.kmplot.com) and the UCSC
Cancer Genomics Browser (https://genome-cancer.
ucsc.edu/proj/site/hgHeatmap/). For a detailed de-
scription of our computational workflow, evaluation
criteria and datasets, refer to Supplementary Materials
(Supplementary Figure S1).
Evaluation for molecular classification of
breast tumours
Figure 2 shows that most signatures were able to
classify breast tumours with 70% accuracy, with
Notch, DDR, Cell cycle, PI3K and Ras showing
the best performance among the pathways, and
MammaPrint and OncotypeDX the best among
the prognostic signatures. This is interesting given
the fact that most signatures share few genes
(Supplementary Figure S7). Most signatures were
also able to classify tumours based on ER status
with 80% accuracy (Supplementary Figure S3).
This was despite ER not being a part of all the sig-
natures; this is likely due to the presence of several
ER targets (e.g. GATA3) or regulators of ER (e.g.
FOXA1) in these signatures. However, most signa-
tures showed a relatively lower performance for
tumour-stage classification (Supplementary Figure
S4). A cross-labelling experiment (Supplementary
Tables S1 and S2) predicting the stage of tumours
from different molecular subtypes showed that while
100% of all subtypes were designated as early stage by
the prognostic signatures, about 10–17% of tumours
(the highest being HER2þ and luminal-B, 17%)
were designated as advanced stage by PAM50 and
the biological pathways, indicating an extent of dis-
agreement between prognostic signatures and path-
ways. We hypothesize that dysregulation of
oncogenic pathways occurs before manifesting as
clinical outcomes, and therefore might reflect the
disease in its advanced stages, whereas genes involved
in symptomatic changes mostly comprise the prog-
nostic signatures, and are still reflecting early stages.
Evaluation for prognosis estimation
Figure 3 shows the survival plots (survival percentage
versus days to death) for all signatures. As expected,
the widely adopted OncotypeDX showed the best
differentiating ability between good and bad prog-
nosis diseases (log-rank test P<0.0021), followed by
MammaPrint (P<0.0043). Wnt (P<0.019), Notch
(P<0.023) and PI3K (P<0.023) showed reasonably
good prognostic ability among the oncogenic path-
ways. Interestingly, the blood signature (P<0.0025)
performed better than the pathways, indicating this
could be a first-level, easy-to-use test to determine
prognosis of the disease in patients.
Combining molecular and prognostic
signatures
An interesting observation from our experiments is
that biological pathways, which are typically not em-
ployed to estimate prognosis, show reasonably good
Table 1: Biological pathways and prognostic signatures
used in our experiments
Signature type Signature Number
of genes
Source
Benchmark PAM50 50 Parker et al. [18]
MammaPrint 70 van’t Veer et al. [19]
Prognostic Wang-76 76 Wang et al. [20]
OncotypeDX 21 Paik et al. [21]
Blood 14 Zhang et al. [52]
Cell cycle 114 Liu et al. [53]
DDRa (includes:
HR, NER, BER,
NHEJ, FA, MMR)
182 KEGG [54]
Notch 48 KEGG [54]
Biological PI3K 346 KEGG [54]
Pathways RAS 227 KEGG [54]
RB 159 KEGG [54]
TGF-b 80 KEGG [54]
Wnt 139 KEGG [54]
Note: aDDR: DNA-damage response; HR: homologous recombination;
NER: nucleotide excision repair; BER: base excision repair; NHEJ: non-
homologous end joining; FA: Fanconi anaemia; MMR: mismatch repair
pathways.
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performance in differentiating good and bad survival
outcomes, and likewise the prognostic signatures
show good performance in molecular subtyping of
tumours. There is thus considerable association be-
tween molecular and clinical features. In fact, the
four molecular subtypes are known to associate
with distinct survival outcomes (Supplementary
Figure S6), with basal-like and HER2þ tumours
characterized by high aggressiveness and low sur-
vival, compared with luminal-B and luminal-A
tumours.
On this basis, we combined the top-performing
pathways and prognostic signatures via a feature-se-
lection approach and assessed the performance of the
combined signature vis-a' -vis the individual signatures
(Supplementary Figure S8). Figure 4 shows that the
combined signature, although containing only 12
genes (Table 2), showed a better classification per-
formance than the individual signatures did, and
was second only to PAM50. Further, at least four
of these 12 genes showed significant differentiation
ability in survival curves (Supplementary Figure S9).
PI3K/RAS and cell cycle genes are over-represented
in this combined signature. PI3K/RAS are fre-
quently over-expressed in aggressive breast tumours,
especially basal-like, whereas cell cycle genes are
markers of high proliferative rate in tumours.
Over-expression of EGFR and of CKS1B is asso-
ciated with poor survival, and these genes have
been explored as molecular targets in breast
tumour therapy [55, 56].
However, there are a few caveats. A blind com-
bination of all signatures brings in noise, which con-
siderably reduces the performance of the combined
signature. Therefore, the use of a feature selection
method, which essentially selects non-redundant
genes and hence reduces the noise, is critical to this
combination procedure. However, the choice of the
feature selection method also matters here. We tested
several methods and found Forward Selection (FS)
[57] to produce a combined signature that performs
better than any of the component signatures indi-
vidually (Figure 4). This combined signature is not
necessarily the best-performing signature in general
(Discussion).
Classifying familial breast tumours
The molecular subtypes have been defined predom-
inantly based on expression datasets from sporadic
breast tumours, which constitute 93–95% of all
breast tumours. These tumours originate during the
lifetime of patients and are typically diagnosed in
women >40 years. On the other hand, familial
breast tumours (the remaining 5–7%) show high
risk of predisposition right from birth and typically
diagnosed in women <40 years owing to inherited
defects in breast cancer risk genes including BRCA1,
BRCA2 or ATM. Being rarer and mostly re-
stricted to families, much less is known about the
molecular and clinical characteristics of these tu-
mours. Previous studies [58, 59] have noted that
BRCA1 and BRCA2 tumours show distinct
Figure 2: Molecular subtypes. Performance of signatures in classifying breast cancer into molecular subtypes
(basal-like, HER2-enriched, luminal-A and luminal-B), ER-status (ERþ/) and tumour stage (early/advanced). The
accuracies shown here are the median accuracies from 10-fold cross-validation; for the entire range, see
Supplementary Material.
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molecular phenotypes, with BRCA1 tumours being
predominantly ER-negative and developing into
basal-like tumours, and BRCA2 tumours being
predominantly ER-positive and developing into
luminal-like tumours.
Here, we applied our classifier trained on the mo-
lecular subtypes from sporadic breast cancer data
(TCGA) to an independent dataset [58] of 19
BRCA1 and 30 BRCA2 familial tumours, using
PAM50 and our 12-gene signature (Supplementary
Table S4). PAM50 classified about a quarter (26%) of
the BRCA1 tumours as basal-like and the remaining
(74%) as luminal, but most (96%) BRCA2 tumours as
luminal. On the other hand, our 12-gene signature
classified all familial tumours as luminal. This is because
the signature lacked ER-related genes (e.g. ESR1 and
FOXA1) that are present in PAM50 and which are
required for distinguishing basal-like (i.e. ER-negative)
from luminal (i.e. ER-positive) tumours.
DISCUSSION
Over the past 15 years, a significant number of gene
expression signatures in cancer have been published.
The query ‘cancer gene expression signature’ in
PubMed returns >500 results for 2013 alone. The
sheer number of such studies makes it challenging to
judge the applicability of these signatures. Although
signatures such as OncotypeDX and MammaPrint
are being used in the clinic, it is still not clear to
what extent these signatures add prognostic or pre-
dictive value to physical or anatomical characteristics
such as age, grade, nodal involvement and tumour
size [60]. Further, as Venet et al. [23] and others have
shown, a considerable number of these signatures in
fact do not correlate to the underlying tumour biol-
ogy. Even in our analysis, we found that pathways
with no direct evidence for involvement in breast
cancer, and sets of randomly selected genes, or
genes showing no or minimum variation in expres-
sion, performed reasonably well (accuracy 0.70) in
molecular subtyping (Supplementary Figure S10).
Therefore, identifying a single most-effective signa-
ture is challenging, and the functional and retro-
spective validation of signatures is critical before
applying them to patients.
Diagnosis and prediction, although primarily
handled by medical practitioners and pathologists,
are of multidisciplinary concerns. An effective pre-
diction strategy should integrate anatomical, histo-
pathological, prognostic and molecular parameters,
and this should be a continuous process enabled
through constant feedback obtained from patient
monitoring in the clinic to molecular profiling and
Figure 4: Combined gene signature. Comparison of classification performance between individual and the com-
bined gene signatures.The combined signature, consisting of 12 genes, was obtained by combining the best-perform-
ing signatures using a feature selection-based strategy (however, excluding PAM50, which is used only as a
benchmark).Refer to Supplementary Figure S8 for further explanation. Shown here are two methods for feature se-
lectionçFS and Variance. FS/Variance-Oncogenic: Feature-selected (using FS/Variance) set of genes obtained after
combining all oncogenic pathways. FS/Variance-Prognostic: Feature-selected (using FS/Variance) set of genes ob-
tained after combining all prognostic signatures. FS-top: Feature-selected (using FS) set of genes obtained after com-
bining top pathways and prognostic signaturesçthis yielded our 12-gene signature. Variance-top: Feature-selected
(using Variance) set of genes obtained after combining top pathways and prognostic signature.
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bioinformatic analysis (Figure 5). As patients are stra-
tified and treated, any deviation from the expected
course of response to the treatment should be
captured and effectively traced back to molecular
mechanisms, i.e. genes and pathways, driving
the unexpected response. Only such an integra-
tive feedback-based approach can ensure deeper
understanding of cancer mechanisms and aid the de-
velopment of effective drugs and treatment for
patients.
CONCLUSION
With its highly heterogeneous characteristics,
breast cancer provides a challenging test bed for dif-
ferentiating the different diseases (subtypes) that con-
stitute the cancer. Although multiple classification
signatures have been proposed, their sheer number
and lack of concordance pose a challenge to judge
their applicability. Although it is increasingly clear
that intrinsic molecular properties of the disease are
associated with clinical outcomes, the functional
Table 2: 12-gene signature obtained by combining oncogenic pathways and prognostic signatures (PI3K, RAS, DDR,
Cell cycle, MammaPrint and OncotypeDX)
Gene symbol Description Source
signature
Biological function of the encoded protein
CDC45 Cell division cycle 45 Cell cycle An essential protein for initiation of DNA replication, which plays
an important role in loading the DNA polymerase alpha onto
chromatin.
EGFR Epidermal growth factor receptor PI3K A cell surface protein that binds to epidermal growth factor. This
binding induces receptor dimerization and tyrosine autopho-
sphorylation and leads to many cellular responses, including
changes in gene expression, cytoskeletal rearrangement, anti-
apoptosis and increased cell proliferation.
GRB7 Growth factor receptor-bound
protein 7
OncotypeDX An adaptor protein that is known to interact with a number of
receptor tyrosine kinases and signallingmolecules, which plays a
role in the integrin signalling pathway and cell migration by
binding with focal adhesion kinase (FAK).
CHRM2 Cholinergic receptor, muscarinic 2 PI3K Belongs to G protein-coupled receptors family. It binds to acetyl-
choline and is associated to several cellular responses including
adenylate cyclase inhibition, phosphoinositide degeneration and
potassium channel mediation.
SCUBE2 Signal Peptide, CUB and EGF-like 2
domain containing protein 2
OncotypeDX Has GO annotation related to calcium ion binding activity and has
been associated to lung and best cancer.
FGFR4 Fibroblast growth factor receptor 4 PI3K Belongs to fibroblast growth factor receptor family; mitogenic
signalling molecules that have roles in angiogenesis, wound
healing, cell migration, neural outgrowth and embryonic
development.
SHC4 Src Homology 2 Domain-
Containing-Transforming Protein
RAS Has GO annotation related to receptor tyrosine kinase binding
and protein domain-specific binding.
IGF1R Insulin-like growth factor 1 receptor RAS/PI3K Binds insulin-like growth factor with a high affinity.With a tyro-
sine kinase activity, it is highly over-expressed in most malignant
tissues where it functions as an anti-apoptotic agent by enhan-
cing cell survival.
CKS1B CDC28 protein kinase regulatory
subunit 1B
Cell cycle Binds to the catalytic subunit of the cyclin-dependent kinases and
is essential for their biological function.
CDKN3 Cyclin-dependent kinase inhibitor 3 Cell cycle Dephosphorylates and eventually prevents the activation of CDK2
kinase. May play a role in cell cycle regulation.
LAMC2 Laminin, gamma 2 PI3K Belongs to an extracellular matrix glycoprotein family. Have been
associated to a wide variety of biological processes including cell
adhesion, differentiation, migration, signalling, neurite out-
growth and metastasis.
PRKX Protein kinase, X-linked RAS A serine/threonine protein kinase regulated by and mediating
cAMP signalling in cells and has multiple functions in cellular dif-
ferentiation and epithelial morphogenesis, also involves in
angiogenesis through stimulation of endothelial cell prolifer-
ation, migration and vascular-like structure formation.
Note:The gene descriptions and biological functions were obtained fromGeneCards (http://www.genecards.org/).
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interpretation of most of these signatures is not clear.
Here, we report a simple experiment to evaluate
these signatures for their capability to classify breast
cancer based on molecular subtypes and disease
prognosis, and attempt to understand the association
between molecular properties and clinical outcomes.
We conclude that an effective prediction model
should integrate anatomical, histopathological, mo-
lecular and prognostic parameters to enable better
drug discovery as well as patient treatment strategies.
SUPPLEMENTARYDATA
Supplementary data are available online at http://
bib.oxfordjournals.org/.
Key Points
 The heterogeneity of breast cancer poses a challenging test bed
for the development of classification techniques.
 Many of the gene expression-based signatures proposed for
breast cancer classification show considerable disagreement
and lack functional interpretation.
 Biological pathways including DNA-damage response, cell cycle
andoncogenicpathways togetherwith a fewprognostic signatures
such as OncotypeDX and MammaPrint show good performance
in classifying breast cancer and estimating clinical outcomes.
 Aneffectivepredictionmodel should combine anatomical, histo-
pathological, molecular and prognostic parameters through a
continuous feedback-based approach to enable effective drug
discovery and treatment strategies.
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